- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.12. | Prime Medicine, Inc.: Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease | 1 | GlobeNewswire (USA) | ||
| PRIME MEDICINE Aktie jetzt für 0€ handeln | |||||
| 13.11. | Goldman Sachs reiterates Early-Stage Biotech rating on Prime Medicine stock | 3 | Investing.com | ||
| 07.11. | Prime Medicine GAAP EPS of -$0.32 misses by $0.06, revenue of $1.2M misses by $1.6M | 2 | Seeking Alpha | ||
| 07.11. | Prime Medicine, Inc.: Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates | 1.902 | GlobeNewswire (Europe) | -- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as... ► Artikel lesen | |
| 07.11. | Prime Medicine, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.11. | Prime Medicine, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11. | Prime Medicine appoints Matthew Hawryluk as chief business officer | 2 | Investing.com | ||
| 03.11. | Prime Medicine, Inc.: Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer | 202 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies... ► Artikel lesen | |
| 30.10. | Prime Medicine, Inc.: Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy | 7 | GlobeNewswire (USA) | ||
| 08.09. | Prime Medicine, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Guggenheim cuts Prime Medicine stock price target to $5 from $18 | 3 | Investing.com | ||
| 13.08. | Guggenheim senkt Kursziel für Prime Medicine drastisch auf 5 US-Dollar | 4 | Investing.com Deutsch | ||
| 08.08. | Chardan senkt Kursziel für Prime Medicine auf 10 US-Dollar | 2 | Investing.com Deutsch | ||
| 08.08. | Prime Medicine stock price target lowered to $10 at Chardan on cash update | 1 | Investing.com | ||
| 07.08. | Prime Medicine, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | 493 | GlobeNewswire (Europe) | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen | |
| 01.08. | Prime Medicine, Inc.: Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares | 2 | GlobeNewswire (USA) | ||
| 01.08. | Cathie Wood's ARK buys Prime Medicine, sells CRISPR stock | 4 | Investing.com | ||
| 31.07. | Prime Medicine, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | Prime Medicine stock falls after pricing public offering | 1 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | +3,14 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| CUREVAC | 3,478 | +1,70 % | Wochenend-Update: Curevac-Aktie im Fokus - was Anleger jetzt wissen müssen! | ||
| MODERNA | 27,580 | -9,19 % | Forget Moderna Stock, This is a Much Better Buy | ||
| AMGEN | 279,55 | -0,50 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| NOVAVAX | 5,766 | -2,24 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 146,80 | -2,23 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| ILLUMINA | 114,98 | -1,42 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,000 | -3,69 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| MAINZ BIOMED | 1,270 | +8,55 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,810 | +3,37 % | Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) | ||
| INTELLIA THERAPEUTICS | 7,816 | -2,66 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 55,50 | -2,63 % | How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up | ||
| BIOCRYST PHARMACEUTICALS | 6,362 | +2,05 % | XFRA BO1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,405 | -7,53 % | NurExone startet Vorbereitung für ExoPTEN-Klinikproduktion |
PRIME MEDICINE INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,070 (-1,96 %) liegt der Kurs bei 3,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRIME MEDICINE INC finden Sie auf Wallstreet Online.